Significance of neoadjuvant therapy before radical prostatectomy

被引:0
|
作者
Paul, R [1 ]
van Randenborgh, H [1 ]
Kübler, H [1 ]
Alschibaja, M [1 ]
Hartung, R [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, D-81675 Munich, Germany
来源
UROLOGE A | 2004年 / 43卷 / 06期
关键词
prostate cancer; neoadjuvant therapy; hormonal therapy; chemotherapy;
D O I
10.1007/s00120-004-0582-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Neoadjuvant therapy before radical prostatectomy should increase survival in patients. This is necessary especially in patients with adverse prognostic factors for locally advanced disease, because in this stage radical prostatectomy as the only treatment results in a significantly reduced rate of progression-free survival. The aim of neo-adjuvant therapy protocols is to increase local tumor control because of possible downstaging effects of the tumor and to improve systemic control because of elimination of circulating tumor cells and possible micrometastases. This review discusses the present and future aspects of neoadjuvant therapies in detail. The neoadjuvant hormonal therapy prior to radical prostatectomy results in a significant downstaging that does not translate into prolonged disease-free survival. This observation was made for short-term (3 months) and long-term (8 months) hormonal therapy. Therefore, neoadjuvant hormonal therapy has only a cosmetic effect on the pathological results and should not be advocated any more. Newer protocols have shown that neoadjuvant chemotherapy or hormone chemotherapy is feasible. The results obtained in non-randomized trials with small numbers of patients do not allow analyzing the efficacy of these protocols. Theoretically, neoadjuvant chemotherapy, especially a taxane-based protocol, which has shown efficacy in hormone-refractory disease, could improve disease outcome. Clinical trials are underway to prove this hypothesis. In the future, new therapeutic strategies could also be used in the neoadjuvant setting. It can only be speculated if antibody protocols or gene therapy will be used in this respect. In conclusion, there is no standard neoadjuvant protocol prior to radical prostatectomy. Whether chemotherapy will set a new standard for care has to be elucidated by the ongoing clinical trials.
引用
收藏
页码:680 / +
页数:7
相关论文
共 50 条
  • [31] Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out
    Van Poppel, H
    EUROPEAN UROLOGY, 2001, 39 : 10 - 14
  • [32] Neoadjuvant hormonal therapy prior to radical prostatectomy: The European experience
    Debruyne, FMJ
    Witjes, WPJ
    MOLECULAR UROLOGY, 2000, 4 (03) : 251 - 256
  • [33] Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls
    Gleave, ME
    La Bianca, S
    Goldenberg, SL
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (03) : 136 - 144
  • [34] The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
    L Tosco
    A Laenen
    A Briganti
    P Gontero
    R J Karnes
    M Albersen
    P J Bastian
    P Chlosta
    F Claessens
    F K Chun
    W Everaerts
    C Gratzke
    M Graefen
    B Kneitz
    G Marchioro
    R S Salas
    B Tombal
    T Van den Broeck
    L Moris
    A Battaglia
    H van der Poel
    J Walz
    A Bossi
    G De Meerleer
    K Haustermans
    H Van Poppel
    M Spahn
    S Joniau
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 407 - 412
  • [35] Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
    Oh, WK
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (03) : 229 - 234
  • [36] Neoadjuvant hormone therapy before radical prostatectomy: Update on the memorial Sloan-Kettering Cancer Center trials
    Fair, WR
    Rabbani, F
    Bastar, A
    Betancourt, J
    MOLECULAR UROLOGY, 1999, 3 (03) : 253 - 260
  • [37] The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
    Tosco, L.
    Laenen, A.
    Briganti, A.
    Gontero, P.
    Karnes, R. J.
    Albersen, M.
    Bastian, P. J.
    Chlosta, P.
    Claessens, F.
    Chun, F. K.
    Everaerts, W.
    Gratzke, C.
    Graefen, M.
    Kneitz, B.
    Marchioro, G.
    Salas, R. S.
    Tombal, B.
    Van den Broeck, T.
    Moris, L.
    Battaglia, A.
    Van der Poel, H.
    Walz, J.
    Bossi, A.
    De Meerleer, G.
    Haustermans, K.
    Van Poppel, H.
    Spahn, M.
    Joniau, S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (04) : 407 - 412
  • [38] Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review
    Fan, Junjie
    Jiang, Zhangdong
    Wang, Guojing
    He, Dalin
    Wu, Kaijie
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2024, 12 (01): : 1 - 7
  • [39] Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer
    Dalkin, BL
    Ahmann, FR
    Nagle, R
    Johnson, CS
    JOURNAL OF UROLOGY, 1996, 155 (04): : 1357 - 1360
  • [40] NEOADJUVANT COMBINATION THERAPY OF DOCETAXEL AND COMPLETE ANDROGEN DEPRIVATION FOR LOCALIZED HIGH RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY
    Thalgott, M. K.
    Treiber, U.
    Maurer, T.
    Heck, M.
    Eiber, M.
    Reimer, B.
    Herkommer, K.
    Paul, R.
    Retz, M.
    Gschwend, J. E.
    Kuebler, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 226 - 226